Compounds, compositions and methods are provided for modulating the RNAi pathway. The compositions comprise oligonucleotides, targeted to nucleic acid molecules encoding EIF2C2. Methods of using these compounds for modulation of RNA interference as well as EIF2C2 expression and for diagnosis and treatment of disease associated with expression of EIF2C2 are provided. Also provided are compounds, compositions and methods for modulating the expression of DDX36. The compositions comprise oligonucleotides, targeted to nucleic acid encoding DDX36. Methods of using these compounds for modulation of DDX36 expression and for diagnosis and treatment of diseases and conditions associated with expression of DDX36 are provided.
Claims What is claimed is: 1. A method of reducing the expression of EIF2C2 in a cell by at least 50% comprising contacting the cell with an antisense compound consisting of 15 to 30 linked nucleosides in which the entire nucleobase sequence of the antisense compound is at least 90% complementary to a nucleobase sequence within nucleotides 1938 to 2572 of SEQ ID NO: 4; and thereby reducing the expression of EIF2C2 in the cell by at least 50%. 2. The method of claim 1 wherein said antisense compound is single-stranded. 3. The method of claim 2 wherein said single-stranded compound is single-stranded RNA. 4. The method of claim 2 wherein said single-stranded compound is a RNase H oligonucleotide. 5. The method of claim 4 wherein said RNase H oligonucleotide is a chimeric oligonucleotide. 6. The method of claim 5 wherein the chimeric oligonucleotide comprises at least one modification selected from the group consisting of a modified internucleoside linkage, a modified sugar residue and a modified nucleobase. 7. The method of claim 6 wherein the modified internucleoside linkage is a phosphorothioate. 8. The method of claim 6 wherein the modified sugar residue is a 2'-O-methoxyethyl. 9. The method of claim 6 wherein the modified nucleobase is 5-methylcytosine. 10. The method of claim 5 wherein the chimeric oligonucleotide comprises a first region having 2'-deoxyribonucleotides and a second and a third region each having 2'-O-methoxyethyl nucleotides, wherein said second and said third regions flank said first region. 11. The method of claim 10 wherein said first region consists often 2'-deoxyribonucleotides and said second and said third regions each consist of five 2'-O-methoxyethyl nucleotides. 12. The method of claim 11 wherein said chimeric oligonucleotide further comprises phosphorothioate internucleoside linkages at each position. 13. The method of claim 12 wherein each cytosine residue of said chimeric oligonucleotide is replaced with 5-methylcytosine. 14. The method of claim 1 wherein said antisense compound is double-stranded. 15. The method of claim 14 wherein the double-stranded compound comprises a sense strand and an antisense strand. 16. The method of claim 15 wherein each strand is 21 nucleobases in length. 17. The method of claim 15 wherein the sense strand and antisense strand are complementary over their entire length. 18. The method of claim 15 wherein at least one of said sense strand and said antisense strand has a two nucleobase overhang on the 3' end. 19. The method of claim 18 wherein the overhang consists of two deoxythymidine residues. 20. The method of claim 15 wherein the internucleoside linkages of said sense strand and said antisense strand are phosphodiester. 21. The method of claim 1 wherein the entire nucleobase sequence of the antisense compound is at least 95% complementary to a nucleobase sequence within nucleotides 1938 to 2572 of SEQ ID NO: 4. 22. The method of claim 1 wherein the entire nucleobase sequence of the antisense compound is 100% complementary to a nucleobase sequence within nucleotides 1938 to 2572 of SEQ ID NO: 4. 23. The method of claim 1, wherein the antisense compound has a nucleobase sequence selected from the nucleobase sequences designated as SEQ ID NOs 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, and 46. 24. The method of claim 1 wherein the antisense compound is an oligonucleotide, wherein the oligonucleotide consists of a gap segment consisting of linked 2'-deoxynucleosides, a 5' wing segment consisting of linked nucleosides, and a 3' wing segment consisting of linked nucleosides; wherein the sugar of each nucleoside of the 5' wing segment is a modified sugar, the sugar of each nucleoside of the 3' wing segment is a modified sugar, and each internucleoside linkage is a phosphorothioate internucleoside linkage. 25. The method of claim 24 wherein the modified sugar is a 2'-O-methoxyethyl sugar. 26. The method of claim 1 wherein the antisense compound is an oligonucleotide, wherein the oligonucleotide consists of a gap segment consisting often linked 2'-deoxynucleosides, a 5' wing segment consisting of five linked nucleosides, and a 3' wing segment consisting of five linked nucleosides; wherein the sugar of each nucleoside of the 5' wing segment is a 2'-O-methoxyethyl sugar, the sugar of each nucleoside of the 3' wing segment is a 2'-O-methoxyethyl sugar, and each internucleoside linkage is a phosphorothioate internucleoside linkage. 27. The method of claim 26 wherein at least one cytosine is a 5-methylcytosine. 28. The method of claim 27, wherein each cytosine is a 5-methylcytosine. 29. The method of claim 28, wherein the antisense compound has a nucleobase sequence comprising at least 8 contiguous nucleobases of a nucleobase sequence selected from the nucleobase sequences designated as SEQ ID NOs 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, and 46. 30. A method of reducing the expression of EIF2C2 in a cell by at least 50% comprising contacting the cell with an oligonucleotide consisting of 15 to 30 linked nucleosides, wherein the entire nucleobase sequence of the oligonucleotide is at least 90% complementary to a nucleobase sequence within nucleotides 1938 to 2572 of SEQ ID NO: 4; and thereby reducing the expression of EIF2C2 in the cell by at least 50%. 31. The method of claim 30, wherein at least one internucleoside linkage is a modified internucleoside linkage. 32. The method of claim 31, wherein each internucleoside linkage is a phosphorothioate internucleoside linkage. 33. The method of claim 30, wherein at least one nucleoside comprises a modified sugar. 34. The method of claim 33, wherein the modified sugar is a bicyclic sugar. 35. The method of claim 33, wherein the modified sugar is a 2'-O-methoxyethyl sugar. 36. The method of claim 30, wherein at least one nucleoside comprises a modified nucleobase. 37. The method of claim 36, wherein the modified nucleobase is a 5-methylcytosine. 38. The method of claim 30, wherein the oligonucleotide has a nucleobase sequence comprising at least 8 contiguous nucleobases of a nucleobase sequence selected from the nucleobase sequences designated as SEQ ID NOs 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, and 46. 39. The method of claim 30, wherein the oligonucleotide has a nucleobase sequence selected from the nucleobase sequences designated as SEQ ID NOs 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, and 46. 40. The method of claim 30 wherein the oligonucleotide consists of a gap segment consisting of linked 2'-deoxynucleosides, a 5' wing segment consisting of linked nucleosides, and a 3' wing segment consisting of linked nucleosides; wherein the sugar of each nucleoside of the 5' wing segment is a modified sugar, the sugar of each nucleoside of the 3' wing segment is a modified sugar, and each internucleoside linkage is a phosphorothioate internucleoside linkage. 41. The method of claim 40 wherein the modified sugar is a 2'-O-methoxyethyl sugar. 42. The method of claim 30 wherein the oligonucleotide consists of a gap segment consisting often linked 2'-deoxynucleosides, a 5' wing segment consisting of five linked nucleosides, and a 3' wing segment consisting of five linked nucleosides; wherein the sugar of each nucleoside of the 5' wing segment is a 2'-O-methoxyethyl sugar, the sugar of each nucleoside of the 3' wing segment is a 2'-O-methoxyethyl sugar, and each internucleoside linkage is a phosphorothioate internucleoside linkage. 43. The method of claim 42 wherein at least one cytosine is a 5-methylcytosine. 44. The method of claim 43, wherein each cytosine is a 5-methylcytosine. 45. The method of claim 44, wherein the oligonucleotide has a nucleobase sequence comprising at least 8 consecutive nucleobases of a nucleobase sequence selected from the nucleobase sequences designated as SEQ ID NOs 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, and 46. 46. The method of claim 44, wherein the oligonucleotide has a nucleobase sequence selected from the nucleobase sequences designated as SEQ ID NOs 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, and 46. 47. The method of claim 30 wherein the entire nucleobase sequence of the oligonucleotide is at least 95% complementary to a nucleobase sequence within nucleotides 1938 to 2572 of SEQ ID NO: 4. 48. The method of claim 30 wherein the entire nucleobase sequence of the oligonucleotide is 100% complementary to a nucleobase sequence within nucleotides 1938 to 2572 of SEQ ID NO: 4. 49. The method of claim 30 wherein the antisense compound is complementary to a nucleobase sequence within nucleotides 1938 to 2572 of SEQ ID NO: 4. 50. The method of claim 1, wherein the oligonucleotide has a nucleobase sequence selected from the nucleobase sequences designated as SEQ ID NOs 24, 33, and 45. 51. The method of claim 30, wherein the oligonucleotide has a nucleobase sequence selected from the nucleobase sequences designated as SEQ ID NOs 24, 33, and 45. 